Extension of in vivo half-life of biologically active molecules by XTEN protein polymers

Journal of Controlled Release

Volumn 240, Issue , 2016, Pages 52-66

  Podust, Vladimir N ^a   Balan, Sibu ^a   Sim, Bee Cheng ^a   Coyle, Michael P ^a   Ernst, Ulrich ^a   Peters, Robert T ^b   Schellenberger, Volker ^a  

^a Amunix Inc   (United States)

^b BIOGEN   (United States)

Author keywords

Biotherapeutics; Chemical conjugation; Genetic fusion; Half life extension; Peptides; XTEN protein polymer

Indexed keywords

BIODEGRADABLE POLYMERS; CHROMATOGRAPHY; ESCHERICHIA COLI; FUNCTIONAL POLYMERS; MOLECULES; PEPTIDES; POLYMERS;

BIODEGRADABLE PROTEINS; BIOLOGICALLY ACTIVE MOLECULES; BIOTHERAPEUTICS; PHYSICOCHEMICAL PROPERTY; PROTEIN BASED THERAPEUTICS; PROTEIN CHROMATOGRAPHY; PROTEIN POLYMERS; THERAPEUTIC PEPTIDES AND PROTEINS;

PROTEINS;

BLOOD CLOTTING FACTOR; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 2; HUMAN GROWTH HORMONE; POLYMER; POLYPEPTIDE; PROTEIN; UNCLASSIFIED DRUG; XTEN PROTEIN POLYMER; BIOLOGICAL PRODUCT;

ARTICLE; BIODEGRADATION; BIOLOGICAL ACTIVITY; DRUG HALF LIFE; DRUG MANUFACTURE; ESCHERICHIA COLI; GENETIC STABILITY; HUMAN; IMMUNOGENICITY; NONHUMAN; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; THERMOSTABILITY; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; HALF LIFE TIME; PROCEDURES; TRENDS;

ANIMALS; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HALF-LIFE; HUMANS; POLYMERS; PROTEIN STRUCTURE, SECONDARY; PROTEINS;

EID: 84991510807     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.10.038     Document Type: Article

References (101)

1. [1] Ryan, S.M., Mantovani, G., Wang, X., Haddleton, D.M., Brayden, D.J., Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin. Drug Deliv. 5 (2008), 371–783.
2. [2] Bailon, P., Won, C.Y., PEG-modified biopharmaceuticals. Expert Opin. Drug Deliv. 6 (2009), 1–16.
3. [3] Kang, J.S., Deluca, P.P., Lee, K.C., Emerging PEGylated drugs. Expert Opin. Emerg. Drugs 14 (2009), 363–380.
4. [4] Pasut, G., Veronese, F.M., State of the art in PEGylation: the great versatility achieved after forty years of research. J. Control. Release 161 (2012), 461–472.
5. [5] Bendele, A., Seely, J., Richey, C., Sennello, G., Shopp, G., Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol. Sci. 42 (1998), 152–157.
6. [6] European Medicines Agency, CHMP Safety Working Party's response to the PDCO regarding the use of PEGylated drug products in the paediatric population. Ref. Doc. # EMA/CHMP/SWP/647258/2012 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/11/WC500135123.pdf, 2012 (Accessed 16 Oct 2015).
7. [7] Rudmann, D.G., Alston, J.T., Hanson, J.C., Heidel, S., High molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins. Toxicol. Pathol. 41 (2013), 970–983.
8. [8] Armstrong, J.K., Hempel, G., Koling, S., Chan, L.S., Fisher, T., Meiselman, H.J., Garratty, G., Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110 (2007), 103–111.
9. [9] Sherman, M.R., Saifer, M.G., Perez-Ruiz, F., PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv. Drug Deliv. Rev. 60 (2008), 59–68.
10. [10] Schellekens, H., Hennink, W.E., Brinks, V., The immunogenicity of polyethylene glycol: facts and fiction. Pharm. Res. 30 (2013), 1729–1734.
11. [11] Richter, A.W., Akerblom, E., Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int. Arch. Allergy Appl. Immunol. 74 (1984), 36–39.
12. [12] Liu, Y., Reidler, H., Pan, J., Milunic, D., Qin, D., Chen, D., Vallejo, Y.R., Yin, R., A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers. J. Pharmacol. Toxicol. Methods 64 (2011), 238–245.
13. [13] Garay, R.P., El-Gewely, R., Armstrong, J.K., Garratty, G., Richette, P., Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin. Drug Deliv. 9 (2012), 1319–1323.
14. [14] Kontermann, R.E., Therapeutic proteins: strategies to modulate their plasma half-lives. 2012, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany.
15. [15] Pasut, G., Polymers for protein conjugation. Polymers 6 (2014), 160–178.
16. [16] Strohl, W.R., Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs 29 (2015), 215–239.
17. [17] Sockolosky, J.T., Szoka, F.C., The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv. Drug Deliv. Rev. 91 (2015), 109–124.
18. [18] Sand, K.M., Bern, M., Nilsen, J., Noordzij, H.T., Sandlie, I., Andersen, J.T., Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. Front. Immunol., 5, 2014, 682.
19. [19] Schellenberger, V., Wang, C.W., Geething, N.C., Spink, B.J., Campbell, A., To, W., Scholle, M.D., Yin, Y., Yao, Y., Bogin, O., Cleland, J.L., Silverman, J., Stemmer, W.P., A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat. Biotechnol. 27 (2009), 1186–1190.
20. [20] Geething, N.C., To, W., Spink, B.J., Scholle, M.D., Wang, C.W., Yin, Y., Yao, Y., Schellenberger, V., Cleland, J.L., Stemmer, W.P., Silverman, J., Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose. PLoS One, 5, 2010, e10175.
21. [21] Ding, S., Song, M., Sim, B.C., Gu, C., Podust, V.N., Wang, C.W., McLaughlin, B., Shah, T.P., Lax, R., Gast, R., Sharan, R., Vasek, A., Hartman, M.A., Deniston, C., Srinivas, P., Schellenberger, V., Multivalent antiviral XTEN-peptide conjugates with long in vivo half-life and enhanced solubility. Bioconjug. Chem. 25 (2014), 1351–1359.
22. [22] Trathnigg, B., Size-exclusion chromatography of polymers. Encyclopedia of analytical chemistry. 2006, John Wiley & Sons, Ltd, Chichester.
23. [23] Hong, P., Koza, S., Bouvier, E.S., Size-exclusion chromatography for the analysis of protein biotherapeutics and their aggregates. J. Liq. Chromatogr. Relat. Technol. 35 (2012), 2923–2950.
24. [24] Podust, V.N., Sim, B.C., Kothari, D., Henthorn, L., Gu, C., Wang, C.W., McLaughlin, B., Schellenberger, V., Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer. Protein Eng. Des. Sel. 26 (2013), 743–753.
25. [25] Alters, S.E., McLaughlin, B., Spink, B., Lachinyan, T., Wang, C.W., Podust, V., Schellenberger, V., Stemmer, W.P., GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model. PLoS One, 7, 2012, e50630.
26. +-binding proteins, calsequestrin, calmodulin, troponin C, and S-100, with the cationic carbocyanine dye “Stains-all”. J. Biol. Chem. 258 (1983), 11267–11273.
27. [27] Goldberg, H.A., Warner, K.J., The staining of acidic proteins on polyacrylamide gels: enhanced sensitivity and stability of “Stains-all” staining in combination with silver nitrate. Anal. Biochem. 251 (1997), 227–233.
28. [28] Bagal, D., Zhang, H., Schnier, P.D., Gas-phase proton-transfer chemistry coupled with TOF mass spectrometry and ion mobility-MS for the facile analysis of poly(ethylene glycols) and PEGylated polypeptide conjugates. Anal. Chem. 80 (2008), 2408–2418.
29. [29] Huang, L., Gough, P.C., Defelippis, M.R., Characterization of poly(ethylene glycol) and PEGylated products by LC/MS with postcolumn addition of amines. Anal. Chem. 81 (2009), 567–577.
30. [30] Lu, X., Gough, P.C., DeFelippis, M.R., Huang, L., Elucidation of PEGylation site with a combined approach of in-source fragmentation and CID MS/MS. J. Am. Soc. Mass Spectrom. 21 (2010), 810–818.
31. [31] Abzalimov, R.R., Frimpong, A., Kaltashov, I.A., Structural characterization of protein–polymer conjugates. I. Assessing heterogeneity of a small PEGylated protein and mapping conjugation sites using ion exchange chromatography and top-down tandem mass spectrometry. Int. J. Mass Spectrom. 312 (2012), 135–143.
32. [32] Hutanu, D., Darie, C.C., Trends in characterization of PEGylated proteins by mass spectrometry. Mod. Chem. Appl., 2, 2014, 128.
33. [33] Xie, H., Gilar, M., Gebler, J.C., Characterization of protein impurities and site-specific modifications using peptide mapping with liquid chromatography and data independent acquisition mass spectrometry. Anal. Chem. 81 (2009), 5699–5708.
34. [34] Haverick, M., Mengisen, S., Shameem, M., Ambrogelly, A., Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications. MAbs 6 (2014), 852–858.
35. [35] Ratanji, K.D., Derrick, J.P., Dearman, R.J., Kimber, I., Immunogenicity of therapeutic proteins: influence of aggregation. J. Immunotoxicol. 11 (2014), 99–109.
36. [36] Li, Y., Lubchenko, V., Vekilov, P.G., The use of dynamic light scattering and brownian microscopy to characterize protein aggregation. Rev. Sci. Instrum., 82, 2011, 053106.
37. [37] Jezek, J., Rides, M., Derham, B., Moore, J., Cerasoli, E., Simler, R., Perez-Ramirez, B., Viscosity of concentrated therapeutic protein compositions. Adv. Drug Deliv. Rev. 63 (2011), 1107–1117.
38. [38] Du, W., Klibanov, A.M., Hydrophobic salts markedly diminish viscosity of concentrated protein solutions. Biotechnol. Bioeng. 108 (2011), 632–636.
39. [39] Hokputsa, S., Jumel, K., Alexander, C., Harding, S.E., Hydrodynamic characterization of chemically degraded hyaluronic acid. Carbohydr. Polym. 52 (2003), 111–117.
40. [40] Harding, S.E., Sedimentation analysis of polysaccharides. Harding, S.E., Rowe, A.J., Horton, J.C., (eds.) Analytical Ultracentrifugation in Biochemistry and Polymer Science, 1992, Royal Society of Chemistry, Cambridge, 495–513.
41. [41] Haeckel, A., Appler, F., Figge, L., Kratz, H., Lukas, M., Michel, R., Schnorr, J., Zille, M., Hamm, B., Schellenberger, E., XTEN-annexin A5: XTEN allows complete expression of long-circulating protein-based imaging probes as recombinant alternative to PEGylation. J. Nucl. Med. 55 (2014), 508–514.
42. [42] Geoghegan, K.F., Stroh, J.G., Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine. Bioconjug. Chem. 3 (1992), 138–146.
43. [43] Gaertner, H.F., Offord, R.E., Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Bioconjug. Chem. 7 (1996), 38–44.
44. [44] Hermanson, G.T., Bioconjugate Techniques. Third ed., 2013, Elsevier Inc., London, Waltham, San Diego.
45. [45] Crayton, S.H., Elias, D.R., Al Zaki, A., Cheng, Z., Tsourkas, A., ICP-MS analysis of lanthanide-doped nanoparticles as a non-radiative, multiplex approach to quantify biodistribution and blood clearance. Biomaterials 33 (2012), 1509–1519.
46. [46] Elias, A., Crayton, S.H., Warden-Rothman, R., Tsourkas, A., Quantitative comparison of tumor delivery for multiple targeted nanoparticles simultaneously by multiplex ICP-MS. Sci. Report., 4, 2014, 5840.
47. [47] BYETTA, (exenatide) injection prescribing information. AstraZeneca. http://www.azpicentral.com/byetta/pi_byetta.pdf, 2015 (Accessed 16 Oct 2015).
48. [48] Cleland, J., Aronson, R., Humphriss, E., Shore, C.R., Bright, G., Zhou, R., Kipnes, M.S., Safety, pharmacokinetics, and pharmacodynamics of a single subcutaneous dose of VRS-859 in patients with type 2 diabetes. European Association for the Study of Diabetes (EASD) 48th Annual Meeting, Berlin, Germany, 2012.
49. [49] Byetta (Exenatide) Injection, Pharmacology/Toxicology Review and Evaluation. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_Byetta_pharmr.PDF, 2005 (Accessed 16 Oct 2015).
50. [50] Ai, G., Chen, Z., Shan, C., Che, J., Hou, Y., Cheng, Y., Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys. Int. J. Pharm. 353 (2008), 56–64.
51. [51] European Medicines Agency, Assessment report. Revestive teduglutide. Ref. Doc. # EMA/CHMP/525255/2012 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002345/WC500132928.pdf, 2012 (Accessed 16 Oct 2015).
52. [52] Nutropin AQ®, [somatotropin (rDNA origin) injection) prescribing information. 2014, Genentech http://www.gene.com/download/pdf/nutropin_aq_prescribing.pdf (Accessed 16 Oct 2015).
53. [53] GENOTROPIN®, (somatropin [rDNA origin] for injection) prescribing information. http://www.genotropin.com/prescribing-information, 2015 (Accessed 16 Oct 2015).
54. [54] Yuen, K.C., Conway, G.S., Popovic, V., Merriam, G.R., Bailey, T., Hamrahian, A.H., Biller, B.M., Kipnes, M., Moore, J.A., Humphriss, E., Bright, G.M., Cleland, J.L., A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults. J. Clin. Endocrinol. Metab. 98 (2013), 2595–2603.
55. [55] Cho, H., Daniel, T., Buechler, Y.J., Litzinger, D.C., Maio, Z., Putnam, A.M., Kraynov, V.S., Sim, B.C., Bussell, S., Javahishvili, T., Kaphle, S., Viramontes, G., Ong, M., Chu, S., Becky, G.C., Lieu, R., Knudsen, N., Castiglioni, P., Norman, T.C., Axelrod, D.W., Hoffman, A.R., Schultz, P.G., DiMarchi, R.D., Kimmel, B.E., Optimized clinical performance of growth hormone with an expanded genetic code. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 9060–9065.
56. [56] Cleland, J.L., Geething, N.C., Moore, J.A., Rogers, B.C., Spink, B.J., Wang, C.W., Alters, S.E., Stemmer, W.P., Schellenberger, V., A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life. J. Pharm. Sci. 101 (2012), 2744–2754.
57. [57] Osborn, B.L., Sekut, L., Corcoran, M., Poortman, C., Sturm, B., Chen, G., Mather, D., Lin, H.L., Parry, T.J., Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur. J. Pharmacol. 456 (2002), 149–158.
58. [58] Huet, T., Kerbarh, O., Schols, D., Clayette, P., Gauchet, C., Dubreucq, G., Vincent, L., Bompais, H., Mazinghien, R., Querolle, O., Salvador, A., Lemoine, J., Lucidi, B., Balzarini, J., Petitou, M., Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 54 (2010), 134–142.
59. [59] Singh, H., Raghava, G.P., ProPred: prediction of HLA-DR binding sites. Bioinformatics 17 (2001), 1236–1237.
60. [60] Cleland, J., Geething, N., To, W., Spink, B., Lee, L., Yao, Y., Silverman, J., VRS-859, a monthly dosed glucagon-like peptide-1 (GLP-1) analogue, provides long-term glucose control in mouse models and lacks toxicity in mice and monkeys. European Association for the Study of Diabetes (EASD) 46th Annual Meeting, Stockholm, Sweden, 2010.
61. [61] Bright, G.M., Quattrin, T., Kletter, G.B., Desrosiers, P.M., Moore, W.V., Humphriss, E., Cleland, J.L., A Phase 1b/2a study of a new long-acting growth hormone (VRS-317) in pre-pubertal children with growth hormone deficiency (GHD). The Endocrine Society's 95th Annual Meeting & Expo (ENDO 2013), San Francisco, CA, 2013.
62. [62] Bright, G.M., Moore, W.V., Nguyen, H.Q., Kletter, G.B., Miller, B., Rogers, D.G., Humphriss, E., Cleland, J.L., Safety and efficacy results of a 6 month, randomized, multi-center trial of a novel long-acting rhGH (VRS-317) in naïve to treatment, pre-pubertal children with growth hormone deficiency (GHD). The Endocrine Society's 96th Annual Meeting and Expo (ENDO 2014), Chicago, IL, 2014.
63. [63] Bright, G.M., Moore, W.V., Nguyen, H.Q., Kletter, G.B., Miller, B., Rogers, D.G., Ng, D., Humphriss, E., Cleland, J.L., Dose response and 12-month safety and efficacy of VRS-317 in pre-pubertal children with moderate growth hormone deficiency (GHD). The Endocrine Society's 97th Annual Meeting & Expo (ENDO 2015), San Diego, CA, 2015.
64. [64] Rosenfeld, R.G., Bakker, B., Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr. Pract. 14 (2008), 143–154.
65. [65] Desrosiers, P., O'Brien, F., Blethen, S., Patient outcomes in the GHMonitor: the effect of delivery device on compliance and growth. Pediatr. Endocrinol. Rev. 2:Suppl. 3 (2005), 327–331.
66. [66] Kapoor, R.R., Burke, S.A., Sparrow, S.E., Hughes, I.A., Dunger, D.B., Ong, K.K., Acerini, C.L., Monitoring of concordance in growth hormone therapy. Arch. Dis. Child. 93 (2008), 147–148.
67. [67] Hunter, I., de Vries, C., Morris, A., MacDonald, T., Greene, S., Human growth hormone therapy: poor adherence equals poor growth. Arch. Dis. Child, 82(Suppl. 1), 2000, A8 (P28).
68. [68] Cutfield, W.S., Derraik, J.G., Gunn, A.J., Reid, K., Delany, T., Robinson, E., Hofman, P.L., Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS One, 6, 2011, e16223.
69. [69] Comparison of long-acting growth hormone VRS-317 to daily growth hormone in pediatric GHD patients (VELOCITY). ClinicalTrials.gov Identifier: NCT02339090. 2015 https://clinicaltrials.gov/ct2/show/NCT02339090 (Accessed 16 Oct 2015).
70. [70] Versartis trial in pre-pubertal Japanese children with growth hormone deficiency (GHD) to assess long-acting growth hormone (VRS-317). ClinicalTrials.gov Identifier: NCT02413138. https://clinicaltrials.gov/ct2/show/NCT02413138, 2015 (Accessed 16 Oct 2015).
71. [71] Centers for Disease Control & Prevention, Diabetes Report card., 2014 ( http://www.cdc.gov/diabetes/pdfs/library/diabetesreportcard2014.pdf. Accessed 16 Oct 2015).
72. [72] International Diabetes Foundation, IDF Diabetes Atlas. 6th edition, 2014 ( https://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf. Accessed 16 Oct 2015).
73. [73] BYDUREON®, (exenatide extended-release) for injectable suspension prescribing information. 2015, AstraZeneca http://www.azpicentral.com/bydureon/pi_bydureon.pdf (Accessed 16 Oct 2015).
74. [74] Cleland, J.L., Silverman, J., Wang, C.-W., Geething, N., Spink, B., Campbell, A., To, W., Scholle, M.D., Yin, Y., Yao, Y., Stemmer, W.P.C., Schellenberger, V., An extended half-life exenatide construct for weekly administration in the treatment of diabetes mellitus. American Diabetes Association 69th Scientific Sessions, New Orleans, LA, 2009.
75. [75] Hartmann, B., Harr, M.B., Jeppesen, P.B., Wojdemann, M., Deacon, C.F., Mortensen, P.B., Holst, J.J., In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J. Clin. Endocrinol. Metab. 85 (2000), 2884–2888.
76. [76] Marier, J.F., Beliveau, M., Mouksassi, M.S., Shaw, P., Cyran, J., Kesavan, J., Wallens, J., Zahir, H., Wells, D., Caminis, J., Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J. Clin. Pharmacol. 48 (2008), 1289–1299.
77. [77] Marier, J.F., Mouksassi, M.S., Gosselin, N.H., Beliveau, M., Cyran, J., Wallens, J., Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease. J. Clin. Pharmacol. 50 (2010), 36–49.
78. [78] Shafiee, G., Mohajeri-Tehrani, M., Pajouhi, M., Larijani, B., The importance of hypoglycemia in diabetic patients. J. Diabetes Metab. Disord., 11, 2012, 17.
79. [79] Donnelly, L.A., Morris, A.D., Frier, B.M., Ellis, J.D., Donnan, P.T., Durrant, R., Band, M.M., Reekie, G., Leese, G.P., Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet. Med. 22 (2005), 749–755.
80. [80] Luddeke, H.J., Sreenan, S., Aczel, S., Maxeiner, S., Yenigun, M., Kozlovski, P., Gydesen, H., Dornhorst, A., PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes. Metab. 9 (2007), 428–434.
81. [81] McCoy, R.G., Van Houten, H.K., Ziegenfuss, J.Y., Shah, N.D., Wermers, R.A., Smith, S.A., Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 35 (2012), 1897–1901.
82. [82] Kalra, S., Mukherjee, J.J., Venkataraman, S., Bantwal, G., Shaikh, S., Saboo, B., Das, A.K., Ramachandran, A., Hypoglycemia: the neglected complication. Indian J. Endocrinol. Metab. 17 (2013), 819–834.
83. [83] Finfer, S., Chittock, D.R., Su, S.Y., Blair, D., Foster, D., Dhingra, V., Bellomo, R., Cook, D., Dodek, P., Henderson, W.R., Hebert, P.C., Heritier, S., Heyland, D.K., McArthur, C., McDonald, E., Mitchell, I., Myburgh, J.A., Norton, R., Potter, J., Robinson, B.G., Ronco, J.J., Intensive versus conventional glucose control in critically ill patients. N. Engl. J. Med. 360 (2009), 1283–1297.
84. [84] Gerstein, H.C., Miller, M.E., Byington, R.P., Goff, D.C. Jr., Bigger, J.T., Buse, J.B., Cushman, W.C., Genuth, S., Ismail-Beigi, F., Grimm, R.H. Jr., Probstfield, J.L., Simons-Morton, D.G., Friedewald, W.T., Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358 (2008), 2545–2559.
85. [85] Glucagon for injection (rDNA origin). 2012, Elli Lilly http://www.lillyglucagon.com/_assets/pdf/glucagon_web_brochure.pdf (Accessed 16 Oct 2015).
86. [86] Amin, R., Ross, K., Acerini, C.L., Edge, J.A., Warner, J., Dunger, D.B., Hypoglycemia prevalence in prepubertal children with type 1 diabetes on standard insulin regimen: use of continuous glucose monitoring system. Diabetes Care 26 (2003), 662–667.
87. [87] Srivastava, A., Brewer, A.K., Mauser-Bunschoten, E.P., Key, N.S., Kitchen, S., Llinas, A., Ludlam, C.A., Mahlangu, J.N., Mulder, K., Poon, M.C., Street, A., Guidelines for the management of hemophilia. Haemophilia 19 (2013), e1–47.
88. [88] Manco-Johnson, M.J., Abshire, T.C., Shapiro, A.D., Riske, B., Hacker, M.R., Kilcoyne, R., Ingram, J.D., Manco-Johnson, M.L., Funk, S., Jacobson, L., Valentino, L.A., Hoots, W.K., Buchanan, G.R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., Mathew, P., Matsunaga, A., Medeiros, D., Nugent, D., Thomas, G.A., Thompson, A.A., McRedmond, K., Soucie, J.M., Austin, H., Evatt, B.L., Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N. Engl. J. Med. 357 (2007), 535–544.
89. [89] DiMichele, D., Inhibitors in hemophilia: a primer. fourth ed., 2008, World Federation of Hemophilia, Montreal, Quebec, Canada.
90. [90] Powell, J.S., Longer-acting clotting factor concentrates for hemophilia. J. Thromb. Haemost. 13:Suppl. 1 (2015), S167–S175.
91. [91] White, G.C. 2nd, Beebe, A., Nielsen, B., Recombinant factor IX. Thromb. Haemost. 78 (1997), 261–265.
92. [92] Kulman, J., Schellenberger, V., XTENylation of clotting factors to prolong circulating time. National Hemophilia Foundation 11th Workshop on New Technologies and Gene Transfer for Hemophilia, Philadelphia, PA, 2012.
93. [93] Ostergaard, H., Bjelke, J.R., Hansen, L., Petersen, L.C., Pedersen, A.A., Elm, T., Moller, F., Hermit, M.B., Holm, P.K., Krogh, T.N., Petersen, J.M., Ezban, M., Sorensen, B.B., Andersen, M.D., Agerso, H., Ahmadian, H., Balling, K.W., Christiansen, M.L., Knobe, K., Nichols, T.C., Bjorn, S.E., Tranholm, M., Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 118 (2011), 2333–2341.
94. [94] Tan, S., Salas, J., Chen, K., Kistanova, E., Ashworth, T., Acosta, M., Johnson, B., Pape, B., Pierce, G., Light, D., Mei, B., Schellenberger, V., Peters, R., Jiang, H., A platelet-targeted Factor VIIa — XTEN fusion protein with increased circulating half-life and improved clotting activity. XXIV International Society on Thrombosis and Haemostasis Congress, Amsterdam, The Netherlands, 2013.
95. [95] Lenting, P.J., van Mourik, J.A., Mertens, K., The life cycle of coagulation factor VIII in view of its structure and function. Blood 92 (1998), 3983–3996.
96. [96] Toole, J.J., Pittman, D.D., Orr, E.C., Murtha, P., Wasley, L.C., Kaufman, R.J., A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc. Natl. Acad. Sci. U. S. A. 83 (1986), 5939–5942.
97. [97] Kulman, J., Liu, T., Chang, P.-Y.B., Ding, S., Patarroyo-White, S., Goodman, A., Kumar, S., Wang, D., Chhabra, E.S., Mezo, A., Pierce, G., Jiang, H., Mei, B., Schellenberger, V., Peters, R., Identification of Structurally permissive regions in coagulation factor VIII suitable for the insertion of exogenous peptidyl elements. XXIV International Society on Thrombosis and Haemostasis Congress, Amsterdam, The Netherlands, 2013.
98. [98] Liu, T., Kulman, J., Chang, P.-Y.B., Patarroyo-White, S., Drager, D., Ding, S., Chhabra, E.S., Kumar, S., Pape, B., Moore, N., Bardan, S., Goodman, A., Acosta, M., Pierce, G., Schellenberger, V., Mei, B., Peters, R., Jiang, H., A combinatorial library approach to generate rFVIII variants with multiple XTEN insertions and improved pharmacokinetic properties. XXIV International Society on Thrombosis and Haemostasis Congress, Amsterdam, The Netherlands, 2013.
99. [99] Liu, T., Chhabra, E.S., Kulman, J., Zhu, L., Patarroyo-White, S., Drager, D., Pape, B., Moore, N., Goodman, A., Pierce, G., Schellenberger, V., Peters, R., Mei, B., Jiang, H., A new class of coagulation factor VIII molecules that achieved 4-fold longer half-life than recombinant FVIII in HemA mice. XXIV International Society on Thrombosis and Haemostasis Congress, Amsterdam, The Netherlands, 2013.
100. [100] Qu, H., O'Farrell, L.S., Wainscott, D.B., Wilbur, K.L., Coskun, T., Mezo, A.R., Schellenberger, V., Podust, V., Glucagon-GLP1-XTEN hybrid peptides: synthesis, in vitro activity and efficacy in DIO mice. American Peptide Symposium, Orlando, FL, 2015.
101. [101] Chang, C.N., Rey, M., Bochner, B., Heyneker, H., Gray, G., High-level secretion of human growth hormone by Escherichia coli. Gene 55 (1987), 189–196.